TFRC and breast cancer: This mechanism can also explain the observed decrease in cellular Ru uptake of a stable Ru(II) –phosphine–carboxylato complex by breast cancer cells with silenced TfR1 expression [75], since a large decrease in cellular TfR1 would greatly decrease Tf-TfR1 endocytosis and, hence, drug uptake.